[
Axis Securities has set a target price of Rs 2,500 on Lupin, showing an upside potential of around 27% from the current market prices.
“New launches in the U.S. market, such as Darunavir and Spiriva, have gained market shares of up to 30% and 25%, respectively. The recent approval for gMegabran has the potential to contribute $50 Mn in annual incremental sales. Additionally, approvals for Tolvaptan (market size $287 Mn) and Xyway (market size $958 Mn with 180-day exclusivity) could drive growth in the second half. The company has a robust product pipeline, which includes Cyanocobalamin, Diazepam Gel, Varenicline, Bromfenac, Glucagen, and Risperidone, among others,” it said.
https://img.etimg.com/thumb/msid-120002213,width-1070,height-580,overlay-etmarkets/slideshow.jpg
https://economictimes.indiatimes.com/markets/stocks/news/prestige-estates-projects-lupin-among-7-small-midcap-stocks-that-can-rally-up-to-63/top-bets/slideshow/120002213.cms
